Cliff Asness’s Kura Oncology KURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.3M Buy
3,126,727
+1,002,247
+47% +$9.46M 0.01% 950
2026
Q1
$17.3M Sell
2,124,480
-937,732
-31% -$8.06M 0.01% 1088
2025
Q4
$31.8M Buy
3,062,212
+820,020
+37% +$8.6M 0.02% 800
2025
Q3
$19.8M Buy
2,242,192
+1,300,517
+138% +$9.27M 0.01% 852
2025
Q2
$5.43M Buy
941,675
+181,343
+24% +$1.11M ﹤0.01% 1244
2025
Q1
$5.02M Buy
760,332
+610,604
+408% +$4.76M 0.01% 1123
2024
Q4
$1.3M Buy
149,728
+27,213
+22% +$392K ﹤0.01% 1750
2024
Q3
$2.39M Buy
122,515
+40,860
+50% +$828K ﹤0.01% 1416
2024
Q2
$1.68M Buy
81,655
+58,422
+251% +$1.2M ﹤0.01% 1533
2024
Q1
$496K Sell
23,233
-6,757
-23% -$131K ﹤0.01% 1962
2023
Q4
$431K Sell
29,990
-80,649
-73% -$793K ﹤0.01% 1945
2023
Q3
$1.01M Buy
110,639
+96,743
+696% +$982K ﹤0.01% 1594
2023
Q2
$147K Buy
+13,896
New +$164K ﹤0.01% 2115
2021
Q2
Sell
-12,875
Closed -$364K 2267
2021
Q1
$364K Sell
12,875
-2,630
-17% -$83.2K ﹤0.01% 1948
2020
Q4
$506K Buy
+15,505
New +$545K ﹤0.01% 1777
2018
Q4
Sell
-18,354
Closed -$321K 2235
2018
Q3
$321K Buy
18,354
+703
+4% +$13.5K ﹤0.01% 2084
2018
Q2
$321K Sell
17,651
-10,754
-38% -$182K ﹤0.01% 2106
2018
Q1
$533K Buy
+28,405
New +$553K ﹤0.01% 1892

Other funds holding KURA

Cliff Asness's KURA Position: Q2 2026 in Review

Cliff Asness increased its Kura Oncology (KURA) stake by 47% in Q2 2026, buying an estimated $9.46M and bringing the position to 3,126,727 shares worth $34.3M. The position accounts for 0.01% of the portfolio, ranked #950.

Cliff Asness first reported a position in KURA in Q1 2018 and has held it in 18 quarters since. 219 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Cliff Asness held 3,126,727 shares of Kura Oncology worth $34.3M as of Q2 2026.
  • Cliff Asness bought 1,002,247 Kura Oncology shares in Q2 2026, an estimated $9.46M.
  • Kura Oncology made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #950 holding.
  • Cliff Asness first reported a position in Kura Oncology in Q1 2018 and has held it in 18 quarters since.
  • 219 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.